The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Table 3 Summary of pooled results regarding serum variables about hepatic fibrosis

Variable	Studies included (n)	Patients included (n)	SMD	95%CI	Significance, P	Heterogeneity
Variable	Studies included (n)	Patients included (n)	SMD	95%CI	Significance, P	P	I²
HA
After treatment, EG vs. CG	1	114	−2.38	−2.87, −1.89	< 0.00001	NA	NA
PC-III
After treatment, EG vs. CG	1	114	−2.92	−4.42, −1.43	< 0.00001	NA	NA
LN
After treatment, EG vs. CG	1	114	−1.99	−4.50, 0.52	0.06	NA	NA
C-IV
vAfter treatment, EG vs. CG	1	114	−2.60	−3.86, −1.33	< 0.0001	NA	NA

CG control group, the group with ETV monotherapy, EG experimental group, the group with ETV plus Tα1 combination therapy, SMD standardized mean difference, CI confidence interval, HA hyaluronic acid, PC-III precollagen III, LN laminin, C-IV type IV collagen, NA not applicable

ISSN: 1471-230X